- Home
- GDL vs VRCA Comparison
GDL vs VRCA Comparison
Compare GDL & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDL | VRCA |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.4M | 112.4M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GDL | VRCA |
|---|---|---|
| Price | $8.62 | $7.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 11.2K | ★ 147.3K |
| Earning Date | 01-01-0001 | 03-10-2026 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,829,000.00 |
| Revenue This Year | N/A | $372.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 234.73 |
| 52 Week Low | $7.65 | $3.28 |
| 52 Week High | $8.13 | $9.82 |
Technical Indicators
Market Signals| Indicator | GDL | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 66.61 | 49.44 |
| Support Level | $8.34 | $7.05 |
| Resistance Level | $8.65 | $8.24 |
| Average True Range (ATR) | 0.09 | 0.41 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 90.91 | 40.34 |
Price Performance
Historical ComparisonAbout GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.